

On page 53, line 24, at the end of that line, please insert --(SEQ ID NO:12)--.

NE { In Figure 1B, at the end of line 13, please insert --(SEQ ID NO:13)--.
In Figure 1B, at the end of line 5, please insert --(SEQ ID NO:14)--.

See ins 21
In the specification at page 57, immediately prior to the claims, please insert the enclosed 7 page text entitled SEQUENCE LISTING as new pages 57-63.

Please renumber original pages 57-59 as new pages 64-66.

IN THE CLAIMS:

sub 31
2
1. (Amended) A vascular endothelial cell growth factor (VEGF) antagonist molecule comprising a variant [vascular endothelial growth factor] VEGF polypeptide, said variant polypeptide comprising an amino acid modification of at least one cysteine residue, wherein said amino acid modification inhibits the ability of said variant polypeptide to properly dimerize with another [vascular endothelial growth factor] VEGF polypeptide monomer, wherein said antagonist molecule is capable of binding to [vascular endothelial growth factor] VEGF receptors without significantly inducing a [vascular endothelial growth factor] VEGF response[, and functional derivatives of said antagonist molecule].

REMARKS

Claims 1-14 remain pending for prosecution in the present application. Applicants have herein amended Claim 1 to further clarify the subject matter being claimed.